Singleron Biotechnologies recently completed its oversubscribed Series B financing, raising close to $100M.
Join our free webinar to get to know our new fully automated tissue dissociation system!
Discover how to use advanced single-cell multi-omics analysis tools to simultaneously analyze tumor genetic variants and microenvironment
Genomeweb article titled “China's Singleron Biotechnologies Pushes Single-Cell RNA-seq Into Clinical, Translational Studies”
Singleron will present at BioRN conference on October 1st, 2021. Where: Halle02, Zollhofgarten 2, 69115 Heidelberg
October 8-9, 2021 Virtually. "FocuSCOPE: A single cell, multi-omics solution to simultaneously analyze tumor variants and microenvironment"
Singleron will present at CMMC Symposium on September 26-28, 2021 in Cologne
Singleron has raised in A, A1, A2 about $70M in total and introduced prominent investors such as LAV, CDH, ARCH Venture Partners, CDG Capital, and Tencent as new shareholders of the company.
Singleron' products were used in a Covid-study which was recently published in Cell Research on June 16, 2021
Singleron to present two posters at LifeTime conferences.
Singleron Biotechnologies announced a drug discovery partnership with XtalPi Inc., an AI-powered pharmaceutical technology company.
Singleron Biotechnologies announced its collaboration with Agilent Technologies Inc. (NYSE: A) to accelerate the development and application of single cell sequencing technology.
Singleron completed Series A1 financing of more than $10M, following a recent Series A round that raised $30M
Singleron announced the successful completion of $30 million Series A financing led by Lilly Asia Ventures (LAV)
Report from Wuhan Huoshenshan Hospital to fight against Covid-19
Singleron CEO and founder Dr. Nan Fang to present at WCLC conference on Lung Cancer study
Singleron technologies secured a pre-series A financing worth more than $10M
Copyright © 2022 Singleron Biotechnologies